Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and dose-ranging study of the effects of SCH 527123 in subjects with moderate to severe COPD.

Next Previous
X
Search
Trial Profile

Safety and dose-ranging study of the effects of SCH 527123 in subjects with moderate to severe COPD.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Navarixin (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 16 Sep 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-004287-23).
    • 22 Sep 2010 Results presented at the 20th Annual Congress of the European Respiratory Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top